## BASELINE CHARACTERISTICS DRUG 6a): placebo + baseline ICS + baseline LABA Versus tiotropium + baseline ICS + baseline LABA

| | Placebo + LABA + ICS (at baseline) | Tiotropium + LABA + ICS (at baseline) |
|:------------------------------------|:------------------------------------|:--------------------------------------|
| N | 1462 | 1464 |
| % male | 72.7 | 74.0 |
| GOLD stage I (%) | 0.1 | 0.1 |
| GOLD stage II (%) | 40.9 | 42.8 |
| GOLD stage III (%) | 47.2 | 45.4 |
| GOLD stage IV (%) | 10.1 | 9.9 |
| GOLD stage - missing (%) | 1.7 | 1.8 |
| Mean age (years) | 64.62 | 64.78 |
| Smoking (mean; pack years) | 46.88 | 47.84 |
| Mean COPD duration (years) | 10.12 | 10.29 |
| Mean post bronchodilator FEV1 (litres) | 1.277 | 1.289 |
| Range post bronchodilator FEV1 (litres) | 0.38-2.73 | 0.37-2.65 |
| % mean post bronchodilator predicted FEV1 (litres) | 46.217 | 46.608 |
| Mean SGRQ score | 46.97 | 46.58 |

## Comparison: Tiotropium + baseline ICS + baseline LABA vs placebo + baseline ICS + baseline LABA (Drug 6a)

| outcome | Mean FEV1 (SE)<br>Tiotropium + baseline LABA + baseline ICS | Mean FEV1 (SE)<br>placebo + baseline LABA + baseline ICS | Effect Size (triple therapy versus dual therapy) (95% CI) |
|:----------------------------------------------------------------------|:---------------------------------------------------------|:---------------------------------------------------------|:----------------------------------------------------------|
| Primary outcome: mean post bronchodilator FEV1 (at 1 year- measured in liters) | 1.36 (0.01)<br>N=1210 | 1.30 (0.01)<br>N=1129 | ¹ MD 0.060 (0.042, 0.077), p<0.0001 |
| Primary outcome: mean post bronchodilator FEV1 (at 4 years- measured in liters) | 1.24 (0.01)<br>N=858 | 1.18 (0.01)<br>N=752 | ¹ MD 0.053 L (0.030, 0.076), p<0.0001 |
| mean total SGRQ score at 1 year | 41.00 (0.34)<br>N=1193 | 43.75 (0.36)<br>N=1101 | ¹ MD -2.751 (-3.725, -1.778), p<0.0001 |
| mean total SGRQ score at 4 years | 44.65 (0.47)<br>N=854 | 46.58 (0.50)<br>N=750 | ¹ MD = -1.932 (-3.284, -0.579), p=0.0052 |
| Number of patients with COPD exacerbations | 1052/1464 | 1066/1462 | ² HR 0.86 (0.79, 0.93), p=0.0003 |
| Mean COPD exacerbations per patient year (SE) | 0.85 (0.03) | 1.00 (0.03) | ² Rate ratio 0.85 (0.78, 0.92), p<0.0001 |
| Number of patients with COPD exacerbation requiring hospitalisation | 398/1464 | 442/1462 | ³ HR 0.80 (0.70, 0.92), p=0.0015 |
| Mean hospitalisations for COPD exacerbations per patient year (SE) | 0.16 (0.01) | 0.18 (0.01) | ³ Rate ratio 0.89 (0.75, 1.07), p=0.2212 |
| All-cause Mortality (adjudicated on-treatment and vital status mortality with censoring at 1470 days) | 205/1464 | 220/1462 | ⁴ HR 0.91 (0.76, 1.11), p=0.3548 |

## 근거표 8-2: ICS/LABA + LAMA vs LAMA

| 연구수 | 연구설계 | 비뚤림 위험 | 비일관성 | 비직접성 | 비정밀 | 출판 비뚤림 | 근거수준 |
|:-------|:---------|:------------|:----------|:----------|:--------|:------------|:---------|
| 2      | 무작위대조군연구 | 비뚤림가능성 | 있음      | 없음      | 없음    | 없음        | 낮음     |

Author, year publication: Jung KS, 2012
Title: A randomized, open label, multicenter, phase 4 study for the comparison of efficacy of tiotropium plus salmeterol/fluticasone propionate compared with tiotropium alone in COPD patients
Country: 1 country, 30 academic hospital-based pulmonary clinics in Korea

<PAGE>119